News
The Lancet Global Health journal reports the findings of a study of a host blood test that can find those at high risk of tuberculosis in people living with HIV. The blood mRNA biomarker differentiated between people living with HIV who had active tuberculosis from those without TB, and predicted which individuals would develop TB within 15 months.
Today, on the 26 March 2001 the 1st participant in the first SATVI BCG- randomised clinical trial was enrolled. Adele Baleta writes in the Daily Maverick about the work that the South African Tuberculosis Vaccine Initiative has been doing the past 20 years in fighting TB.
On Friday 26 March 2021, SATVI will celebrate its 20th birthday to mark the enrolment in 2001 of the first participant in the first SATVI TB vaccine trial a randomised controlled trial of intradermal vs percutaneous BCG vaccination, Hawkridge BMJ 2008.
Cape Town: Researchers at the South African Tuberculosis Vaccine Initiative (SATVI) research site in Worcester have started recruitment for a phase II vaccine trial to see if the M72/AS01E TB vaccine is safe and immunogenic in people living with HIV.
Pages
Worcester Site Office:
SATVI Project Office, University of Cape Town, Brewelskloof Hospital, Haarlem Street, WORCESTER, 6850.
Tel: +27 23 346 5400
Fax: +27 23 346 5406
Email: Field Site Manager
Google maps: Click here GPS: -33.620455, 19.458576
Map to Worcester Field Office